Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies using GPCR targets.

The company has secured a product patent each from the African Regional Intellectual Property Organisation (Aripo) and South Korea corresponding to new chemical entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases.

The two patents are valid through 2033 and 2034, respectively.

The granted claims of the patents include the class of selective 5-HT4 and 5-HT6 compounds respectively and are being developed as therapeutic agents for major depressive disorders and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Narcolepsy, Parkinson.

The Company has 9 internally-discovered therapeutic drug candidates, currently in various stages of pre-clinical development targeting ADHD, dementia, depression, Huntington’s disease, Parkinson’s disease and pain.